Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy

Published:2015-04-02 Issue:14 Volume:125 Page:2306-2309
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

de Rooij Martin F. M.¹,Kuil Annemieke¹,Kater Arnon P.²³,Kersten Marie José²³,Pals Steven T.¹³,Spaargaren Marcel¹³

Affiliation:

1. Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

2. Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

3. Lymphoma and Myeloma Center Amsterdam – LYMMCARE, Amsterdam, The Netherlands

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/14/2306/1383985/2306.pdf

Reference10 articles.

1. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

2. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.;Wang;N Engl J Med,2013

3. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.;Byrd;N Engl J Med,2014

4. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.;Brown;Blood,2014

5. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).;Kahl;Blood,2014

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas;British Journal of Haematology;2024-03-19

2. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma;Leukemia;2024-03-07

3. BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance;Clinical Cancer Research;2023-07-13

4. Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr mice;Vascular Pharmacology;2023-06

5. Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies;Frontiers in Oncology;2022-09-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3